These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28130691)

  • 41. Health technology assessment in the United Kingdom.
    Drummond M; Banta D
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():178-81. PubMed ID: 19527538
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10,000/QALY?
    Carroll C; Houten R; Boland A; Kaltenthaler E; Dickson R
    Value Health; 2018 Mar; 21(3):341-350. PubMed ID: 29566842
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The NICE way of influencing health spending: a conversation with Sir Michael Rawlins. Interview by Nicholas Timmins.
    Rawlins M
    Health Aff (Millwood); 2009; 28(5):1360-5. PubMed ID: 19743561
    [TBL] [Abstract][Full Text] [Related]  

  • 44. NICE methodological guidelines and decision making in the National Health Service in England and Wales.
    Gafni A; Birch S; ;
    Pharmacoeconomics; 2003; 21(3):149-57. PubMed ID: 12558466
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single technology appraisals by NICE: are they delivering faster guidance to the NHS?
    Barham L
    Pharmacoeconomics; 2008; 26(12):1037-43. PubMed ID: 19014204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The 'NICE' approach to technology assessment: an economics perspective.
    Birch S; Gafni A
    Health Care Manag Sci; 2004 Feb; 7(1):35-41. PubMed ID: 14977092
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Methodological issues in undertaking independent cost-effectiveness analysis for NICE: the case of therapies for ADHD.
    Griffin SC; Weatherly HL; Richardson GA; Drummond MF
    Eur J Health Econ; 2008 May; 9(2):137-45. PubMed ID: 17476538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NICE accountability for reasonableness: a qualitative study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD).
    Schlander M
    Curr Med Res Opin; 2007 Jan; 23(1):207-22. PubMed ID: 17261237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence.
    Chalkidou K
    Issue Brief (Commonw Fund); 2009 Jul; 59():1-12. PubMed ID: 19639713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Age-related references in national public health, technology appraisal and clinical guidelines and guidance: documentary analysis.
    Forrest LF; Adams J; Ben-Shlomo Y; Buckner S; Payne N; Rimmer M; Salway S; Sowden S; Walters K; White M
    Age Ageing; 2017 May; 46(3):500-508. PubMed ID: 27989991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Economic evaluation: what does a nurse manager need to know?
    Douglas HR; Normand C
    J Nurs Manag; 2005 Sep; 13(5):419-27. PubMed ID: 16108780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
    Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
    Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimating 'costs' for cost-effectiveness analysis.
    Miners A
    Pharmacoeconomics; 2008; 26(9):745-51. PubMed ID: 18767895
    [TBL] [Abstract][Full Text] [Related]  

  • 57. National Institute for Health and Clinical Excellence: the Medical Technologies Evaluation Programme.
    J Med Eng Technol; 2011 Jul; 35(5):283-4. PubMed ID: 21635177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. National Institute for Clinical Excellence: NICE works.
    Rawlins MD
    J R Soc Med; 2015 Jun; 108(6):211-9. PubMed ID: 26085559
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does NICE apply the rule of rescue in its approach to highly specialised technologies?
    Charlton V
    J Med Ethics; 2022 Feb; 48(2):118-125. PubMed ID: 33685978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal.
    Morton A; Adler AI; Bell D; Briggs A; Brouwer W; Claxton K; Craig N; Fischer A; McGregor P; van Baal P
    Health Econ; 2016 Aug; 25(8):933-8. PubMed ID: 27374115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.